Preclinical studies (Burvenich et al. 2018; Kasten et al. 2018) and phase I clinical trials (Modak et al. 2020; Kramer et al. 2022) using radiolabelled antibodies have demonstrated successful radionuclide targeting of B7-H3-expressing tumours. Here, CD276 is linked to neoplasm.